| Name | Title | Contact Details |
|---|
DRE Medical Inc is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Envoy Medical Corporation is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
SWIFT COUNTY BENSON HOSP is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Benson, MN. To find more information about SWIFT COUNTY BENSON HOSP, please visit www.scbh.org
At Lane Regional Medical Center, we value community and take pride in the role we play as caregivers. It is an honor to say that we serve as the primary healthcare resource for more than 200,000 of our neighbors located throughout Zachary and the surrounding region of Baker, Central, Clinton, Jackson, St. Francisville, New Roads, North Baton Rouge and Southern Mississippi. As part of our continued dedication to serving our community and providing the highest quality of care, we continue to recruit new physicians to the area and to provide access to the very best healthcare services, technologies and programs available in the region.
Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.